Fibroblast deletion of ROCK2 attenuates cardiac hypertrophy, fibrosis, and diastolic dysfunction
Toru Shimizu, Nikhil Narang, Phetcharat Chen, Brian Yu, Maura Knapp, Jyothi Janardanan, John Blair, James K. Liao
Toru Shimizu, Nikhil Narang, Phetcharat Chen, Brian Yu, Maura Knapp, Jyothi Janardanan, John Blair, James K. Liao
View: Text | PDF
Research Article Cardiology

Fibroblast deletion of ROCK2 attenuates cardiac hypertrophy, fibrosis, and diastolic dysfunction

Abstract

Although left ventricular (LV) diastolic dysfunction is often associated with hypertension, little is known regarding its underlying pathophysiological mechanism. Here, we show that the actin cytoskeletal regulator, Rho-associated coiled-coil containing kinase-2 (ROCK2), is a critical mediator of LV diastolic dysfunction. In response to angiotensin II (Ang II), mutant mice with fibroblast-specific deletion of ROCK2 (ROCK2Postn–/–) developed less LV wall thickness and fibrosis, along with improved isovolumetric relaxation. This corresponded with decreased connective tissue growth factor (CTGF) and fibroblast growth factor–2 (FGF2) expression in the hearts of ROCK2Postn–/– mice. Indeed, knockdown of ROCK2 in cardiac fibroblasts leads to decreased expression of CTGF and secretion of FGF2, and cardiomyocytes incubated with conditioned media from ROCK2-knockdown cardiac fibroblasts exhibited less hypertrophic response. In contrast, mutant mice with elevated fibroblast ROCK activity exhibited enhanced Ang II–stimulated cardiac hypertrophy and fibrosis. Clinically, higher leukocyte ROCK2 activity was observed in patients with diastolic dysfunction compared with age- and sex-matched controls, and correlated with higher grades of diastolic dysfunction by echocardiography. These findings indicate that fibroblast ROCK2 is necessary to cause cardiac hypertrophy and fibrosis through the induction CTGF and FGF2, and they suggest that targeting ROCK2 may have therapeutic benefits in patients with LV diastolic dysfunction.

Authors

Toru Shimizu, Nikhil Narang, Phetcharat Chen, Brian Yu, Maura Knapp, Jyothi Janardanan, John Blair, James K. Liao

×

Figure 8

Effects of ROCK knockdown on the activated mediators related to cardiac remodeling in response to TGF-β1 in rat neonatal cardiac fibroblasts (RNCFs).

Options: View larger image (or click on image) Download as PowerPoint
Effects of ROCK knockdown on the activated mediators related to cardiac ...
(A and B) Representative immunoblots and densitometric quantification of ROCK activityas assessed by the ratio of phosphorylated form of the myosin-binding subunit (MBS) to total MBS (p-MBS/t-MBS), stimulated by 10 ng/ml TGF-β1 for 24 hours, with or without 10 μM Y27632, a specific ROCK inhibitor, in RNCFs (n = 3–4 each). (C–F) Representative immunoblots and densitometric quantification of FGF2, CTGF, and α-SMA protein expression, stimulated by TGF-β1, with or without Y27632, in RNCFs (n = 3–4 each). **P < 0.01 vs. vehicle-stimulated RNCFs. ##P < 0.01 vs. TGF-β1–stimulated RNCFs without Y27632. (G–J) Representative immunoblots and densitometric quantification of ROCK1 and ROCK2 protein expression and ROCK activity, stimulated by TGF-β1, in RNCFs transfected with control, ROCK1, or ROCK2 siRNA (n = 3–4 each). (K–N) Representative immunoblots and densitometric quantification of FGF2, CTGF, and α-SMA protein expression, stimulated by TGF-β1, in RNCFs transfected with control, ROCK1, or ROCK2 siRNA (n = 3–4 each). **P < 0.01 vs. vehicle-stimulated RNCFs transfected with control siRNA. ##P < 0.01 vs. TGF-β1–stimulated RNCFs transfected with control siRNA. †P < 0.05, ††P < 0.01 vs. TGF-β1–stimulated RNCFs transfected with ROCK1 siRNA. Data are expressed as mean ± SEM. P values were calculated using one-way ANOVA with Tukey’s HSD test.